NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma — Stella

Recruiting

Back to Non Hodgkin Lymphoma (NHL) trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(6 sites)

South Korea

Chonnam National University Hwasun Hospital, Hwasun

Seoul National University Bundang Hospital, Seongnam

Catholic univ of Yeouido St Mary's Hospital, Seoul

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

Key details

Phase

Early testing

Sponsor

NOBO Medicine

Enrollment target

~9 participants

Started

December 2025

Primary completion

December 2026

Age range

19 Years – 80 Years

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov